Form 4: Inmune Bio CFO David Moss Acquires Shares and Warrants in Direct Offering

David Moss, CFO of Inmune Bio, Inc., reports the acquisition of common stock and warrants through a registered direct offering.

Summary

• On September 12, 2024, David Moss, the CFO of Inmune Bio, Inc., acquired 7,690 shares of common stock at $6.375 per share and warrants to purchase 7,690 shares at $0.125 per warrant.
• These securities were obtained through a registered direct offering with an aggregate purchase price of $13,000,000.
• Following the transaction, Moss directly owns 1,275,869 shares of Inmune Bio, Inc.
• The warrants are exercisable on or after March 16, 2025, and expire on March 16, 2030, with a potential extension for insiders during blackout periods.
• The exercise price of the warrants is $6.40 per share, subject to adjustment.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the CFO's purchase suggests confidence, but it's a routine filing and doesn't contain groundbreaking news.

Positives

• The CFO's participation in the direct offering could be seen as a positive signal, indicating confidence in the company's future prospects.
• Increased insider ownership aligns management's interests with those of shareholders.

Future Outlook

The document does not contain specific forward-looking statements beyond the terms of the warrants.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's value and future performance. A purchase by the CFO is generally viewed positively.

Stakeholder Impact

• The CFO's increased stake could reassure shareholders.
• The capital injection from the direct offering benefits the company's financial position.

Key Dates